The EMA’s BSWP’s opinon [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2016-03-04 15:37 (2102 d 08:28 ago) – Posting: # 16051
Views: 10,454

Dear all,

last month I had the displeasure to attend a “scientific” advisory meeting at a Scandivian agency.

Background:Maximum TIE was 0.04987. Power generally >80% unless the very unlikely combination of extremely different group sizes and CVs hits. Even then ~70%. I was satisfied.

The agency’s statistician said (my comments in blue):
The work plan 2016 of the BSWP contains this:

Type I error control in two-stage designs in bioequivalence studies
Action: Continue work related to type I error control in two-stage designs in bioequivalence studies.
Comments: This is done in collaboration with the Pharmacokinetics Working Party.

I fear the worst. But where is the secret recommendation? Today Rev. 13 of the Q&A document was published. Nada.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,785 posts in 4,556 threads, 1,547 registered users;
online 9 (0 registered, 9 guests [including 1 identified bots]).
Forum time: Monday 00:05 CET (Europe/Vienna)

The history of statistics is like a telephone directory:
the plot is boring, full of numbers and the cast is endless.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz